CINECA IRIS Institutional Research Information System

NICOLINI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.041
EU - Europa 3.790
AS - Asia 2.273
AF - Africa 161
SA - Sud America 51
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 2
Totale 17.326
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.661
IT - Italia 1.208
CN - Cina 1.198
SE - Svezia 633
BG - Bulgaria 563
SG - Singapore 441
CA - Canada 376
UA - Ucraina 366
TR - Turchia 348
DE - Germania 278
FI - Finlandia 230
VN - Vietnam 176
GB - Regno Unito 171
CH - Svizzera 142
CI - Costa d'Avorio 116
RU - Federazione Russa 91
HK - Hong Kong 56
BR - Brasile 48
FR - Francia 28
IN - India 23
SN - Senegal 21
BE - Belgio 17
BJ - Benin 16
AT - Austria 12
CZ - Repubblica Ceca 10
NL - Olanda 10
AU - Australia 8
GR - Grecia 8
IR - Iran 5
DK - Danimarca 4
HU - Ungheria 4
ZA - Sudafrica 4
BD - Bangladesh 3
IE - Irlanda 3
IQ - Iraq 3
RO - Romania 3
TH - Thailandia 3
ES - Italia 2
EU - Europa 2
IL - Israele 2
KR - Corea 2
LT - Lituania 2
MU - Mauritius 2
PK - Pakistan 2
PL - Polonia 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AR - Argentina 1
DO - Repubblica Dominicana 1
GT - Guatemala 1
HR - Croazia 1
ID - Indonesia 1
JP - Giappone 1
KG - Kirghizistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
MA - Marocco 1
MX - Messico 1
NG - Nigeria 1
NI - Nicaragua 1
OM - Oman 1
RS - Serbia 1
SA - Arabia Saudita 1
UY - Uruguay 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 17.326
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.423
Ann Arbor 1.238
Chandler 966
Fairfield 918
Houston 883
Sofia 563
Ashburn 493
Jacksonville 483
Milan 469
Santa Clara 392
Seattle 373
Beijing 370
Ottawa 367
Wilmington 354
Cambridge 336
New York 322
Singapore 269
Nanjing 259
Izmir 257
Boardman 242
Princeton 229
Lawrence 220
Medford 214
Des Moines 165
Bern 139
Abidjan 116
Dearborn 101
Istanbul 91
Nanchang 89
Shanghai 87
Jüchen 75
Dong Ket 71
Florence 60
Serra 55
Hong Kong 54
Kunming 53
San Diego 44
Shenyang 43
Hebei 34
Ogden 34
Boulder 33
Rome 33
Tianjin 31
Chicago 30
Falls Church 28
Hefei 23
Redwood City 23
Changsha 22
Dakar 21
Hangzhou 21
Pune 21
Lancaster 20
Los Angeles 20
Jiaxing 19
Norwalk 18
Brussels 17
Düsseldorf 17
Orange 17
Auburn Hills 16
Cotonou 16
Pisa 16
Guangzhou 15
London 15
Frankfurt am Main 13
Lanzhou 13
Jinan 12
Vienna 12
Washington 12
Fuzhou 11
Changchun 10
Genoa 10
Anguillara Sabazia 9
Detroit 9
Nettuno 8
Verona 8
Grafing 7
Helsinki 7
Chongqing 6
Council Bluffs 6
Dallas 6
Indiana 6
Kent 6
Marseille 6
Phoenix 6
São Paulo 6
Wenzhou 6
Lucca 5
Redmond 5
Simi Valley 5
Tappahannock 5
Wuhan 5
Olomouc 4
Prague 4
Viareggio 4
Amsterdam 3
Bremen 3
Chengdu 3
Copenhagen 3
Groningen 3
Jinhua 3
Totale 13.693
Salva come PNG Salva come JPEG
Nome #
Molecular markers in breast cancer: no longer a “free” run from laboratory to the clinic 155
Effect of pulsed electromagnetic field stimulation on knee cartilage, subchondral and epyphiseal trabecular bone of aged Dunkin Hartley guinea pigs 154
Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. 154
T cell-mediated immunity, eosinophils, sIL-2R, neopterin and interleukins 4, 6, 10, 12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 137
Early diagnosis and treatment of breast cancer relapses 136
Are risk factors common to thyroid cancer and nodule? A forty years observational time-trend study 135
A rationale non-invasive schedule with tumor markers and instrumental exsaminations for “early” detection of bone metastases in breast cancer 128
Bone scintigraphy and tumor markers in the post-operative follow-up of breast, colorectal, prostate and renal cancer 128
An iron regulatory gene signature in breast cancer: More than a prognostic genetic profile? 128
Usefulness of CEA, TPA, GICA, CA 72.4, and CA 195 in the Diagnosis of primary colorectal cancer and at its relapse. 126
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 126
Prolonged survival by “early” salvage treatment of breast cancer patients: a retrospective six year study 125
A meta-analysis of the performance of serum tumour markers levels for early signalling distant metastases during post-operative follow-up of disease-free breast cancer patients 124
Quantification of Blood Dendritic Cells in Colorectal Cancer Patients During the Course of Disease 123
Stem Cells: Their Role in Breast Cancer Development and Resistance to Treatment. 120
Accuracy of an individual reference limit (IRL) during intensive post-operative monitoring of disease-free breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel 120
Criteria to use serum tumour marker levels for early signalling distant metastases durino post-operative follow-up of disease-free breast cancer patients: laboratori and clinical aspects. 113
Tumor markers increase the diagnostic accuracy of skeletal metastases in breast cancer patients 112
Additional 5-FU-LV significantly increases survival in gastrointestinal cancer 111
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin (PHA) and NK cytotoxic activity of peripheral blood lymphocytes in patients (pts) mastectomized for breast cancer 110
A rational non invasive schedule with tumor markers, bone scanning (BS) and "aimed" computed tomography (CT) or skeletal x - ray for "early" detection of bone metastases in breast cancer 110
Pilot study with subcutaneous (s.c.) low dose rIL-2 cyclically given in addition to 5-FU and leucovorin (LV) in metastatic colorectal cancer 110
T-cell mediated immunity (CMI) and B lymphocytes in breast cancer patients after mastectomy 110
Postoperative monitoring of breast cancer patients with tumor markers 108
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 108
Immune manipulation of advanced breast cancer: an interpretative model of the relationship between immune system and tumor biology 107
A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect 104
Reducing radiological imaging during post-operative monitoring of breast cancer patients with serum CEA-TPA-CA15.3 tumor marker (TM) panel and an individual reference limit (IRL) 104
Evaluation of CEA, TPA, Ca 15.3, Ca 549 and TPS in the monitoring of metastatic breast cancer 103
Urinary markers of bone resorption in breast cancer patients 103
Atherosclerosis and cancer: common pathways on the vascular endothelium 103
Cancer stem cells: perspectives of new therapeutical approaches for breast cancer 103
Cell mediated immunity in disease free breast cancer patients 102
From the bench to the bedside. Galectin-3 immunodetection for improving the preoperative diagnosis of the follicular thyroid nodules 102
Stem cells: their role in breast cancer development and resistance to treatment. 101
Lymphopressotherapy in chronic postmastectomy lymphedema 100
CEA, TPA, GICA, CA 72-4 and CA 195 and their associations in the post-operative follow-up of colorectal cancer 99
Cell mediated immunity (CMI) in non relapsed breast cancer patients 99
Large needle aspiration biopsy histology for the preoperative selection of the palpable thyroid nodule diagnosed by FNA cytology as microfollicular nodule, microfollicular nodule with atypical cells or suspected cancer 99
Immunotherapy prolongs the serum CEA-TPA-CA15.3 lead time at the metastatic progression in endocrine-dependent breast cancer patients 99
Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial 99
Osteoporosis and biomaterial osteointegration 99
Bioabsorbable scaffold for in situ bone regeneration. 99
Uselfulness of serum CEA, GICA and ferritin measurement in the postoperative follow-up of renal cancer 98
Defining the critical hurdles in cancer immunotherapy. 98
Comparison Between Two Different Dynamic Methods for Evaluating CEA-TPA-CA15.3 Tumor Marker ™ Panel Specificity in the Post-Operative Follow-up of Disease-Free Breast Cancer Patients: Preliminary Results 98
Impact on survival of "early" detection of colorectal cancer relapses with tumor markers 96
Advanced breast cancer: an update and controversies on diagnosis and therapy 96
Comparison of Ca 549 and TPS usefulness with CEA, TPA and Ca 15.3 in the post-operative follow-up of breast cancer patients 95
Cytometric evaluation of mitogenic proliferation response to phytohemagglutinin and NK cytotoxic activity of peripheral blood lymphocytes in patients mastectomized for breast cancer 95
Tumoral markers in the kidney cancer: preliminary results 95
Cell mediated immunity (CMI) in breast cancer patients at the relapse 94
Large needle aspiration biopsy (LNAB) of palpable thyroid nodules refines the two FNA cytological diagnoses of microfollicular nodule and suspected cancer 94
Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. 94
Bone remodeling, humoral networks and smart biomaterial technology for osteoporosis 94
Aspiration needle biopsy refines preoperative diagnosis of thyroid nodules defined at fine needle aspiration as microfollicular nodule 93
Usefulness of serum NSE and S-100 protein in patients with malignant melanoma: preliminary data 92
Microcirculation in chronic post-mastectomy lymphoedem 92
Prognostc value of tissue vascular endothelial growth factor in primary breast cancer 92
Therapy following “early” detection of relapse with the CEA-TPA-CA15.3 panel after mastectomy prolongs overall survival 92
First Line Salvage Hormone Immunotherapy in Endocrine-Dependent Metastatic Breast Cancer 92
Comparison between hydroxyproline (OHP) and deoxypyridinoline (DPD) in the detection of bone metastases in patints with breast cancer and benigne pathology 91
Serum levels of T-lymphocyte subpopulations, eosinophils, sIL-2R, neopterin and IL-4, IL-6, IL-10, IL-12 in metastatic renal and colorectal cancer patients (pts) cyclically treated with low subcutaneous (s.c.) rIL-2 91
Subcutaneous (s.c.) low dose rIL-2 cyclically given increases the response rate (RR) and prolongs the response to 5-FU and LV of metastatic colorectal cancer patients (pts): an update of results 91
A Drug Screening Revealed Novel Potential Agents against Malignant Pleural Mesothelioma 90
TSH levels are affected by time of blood sampling in untreated euthyroid goitrous patients. 90
A rationale follow-up with CEA-TPA-CA15.3 tumor marker panel strongly decreases the conventional instrumental examinations to monitor metastatic breast cancer patients 90
Von Willebrand’s factor mediates the adherence of human tumoral cells to human endothelial cells and ticlopidine interferes with this effect 90
CEA, TPA, GICA, CA 72-4 and CA 195 in the post-operative follow-up of colorectal cancer 89
Comparison between two groups of breast cancer patients submitted or not to a rational post-operative follow-up with tumor markers 88
null 88
Manual lymphatic drainage for chronic post-mastectomy lymphoedema treatment 88
Prognostic indices of overall survival (OS) and response to TAM and MAP in metastatic breast cancer patients 87
Usefulness of a rationale post-operative follow-up of breast cancer with tumor markers 87
intensive post operative follow of breast cancer patients with tumors markers: accuracy of serum MCA,Ca 15,3 and CEA, TPA,CA15.3 tumor maker panel for early detection of relapse. 87
Circulating tumor cells (CTCs) in breast cancer post-operative follow-up: a preliminary comparison with serum CEA-TPA-CA15.3 tumor marker (TM) panel based monitoring. 87
Metastatic colo rectal cancer : a pilot study with multistep therapy. 87
Restaging after neoadjuvant chemoradiotherapy for rectal adenocarcinoma: role of F18-FDG PET 87
CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. 87
Low s.c. rIL-2 doses cyclically given in advanced renal cancer patients 86
A multistep therapy with subcutaneous low dose recombinant interleukin-2, 5-fluorouracil and leucovorin prolongs the response of metastatic colorectal cancer patients: a pilot study 86
Treatment of mild non-chemotherapy-induced iron deficiency anemia in cancer patients: Comparison between oral ferrous bisglycinate chelate and ferrous sulfate. 86
T-cell mediated immunity, eosinophiles, SIL-2R, neopterin and interleukins 4,6,10,12 in metastatic renal and colorectal cancer patients clinically treated with low subcutaneous RIL-2 85
Metastatic breast cancer: an updating 85
Immunological and side effects of low sc recombinant interleukin-2 dose in addition to conventional treatment in relapsed breast and colorectal cancer patients 85
RELATIONSHIP AMONG CIRCULATING LEVELS OF THYROID HORMONES TSH AND TBG AFTER THYROIDECTOMY 84
Our experience with subcutaneous (s.c.) rIL2 therapy in advanced cancer patients 84
Home therapy with low-dose s.c. rIL-2 cycles to prolong the response to 5-FU and leucovorin (LV) in metastatic colorectal cancer 84
Cell mediated immunity in breast cancer patients 84
Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues 84
Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. 84
TSH levels are affected by time of blood sampling in the follow up of levothyroxine substitution therapy: preliminary report 83
In colorectal cancer a multistep therapy with subcutaneous (s.c.) low dose recombinant interleukin-2(rIL-2),5-fluorouracil (5-FU) and leucovorin(LV) prolongs the duration of responce and overall survival of patients with inoperable metastases 83
181) Tumour markers improve cost-effectiveness ratio of post-operative follow-up of breast cancer patients. 83
Preoperative histological diagnosis of palpable thyroid nodules: accuracy of aspiration needle biopsy 82
In colorectal cancer a multistep therapy with subcutaneous (s. c.) low dose recombinant interleukin-2 (rIL-2), 5-fluorouracil (5-FU) and leucovorin (LV) prolongs the duration of response and overall survival of patients with inoperable metastases 82
Methodological and clinical progress in thyroid tumor markers 82
Cytokines in the management of high risk or advanced breast cancer: an update and expectation 82
Early detection of colorectal cancer relapses with tumor markers 81
Cyclin D-1 prognostic value compared to axillary node status (N), ER, PgR, MIB-1 and p53 in breast cancer patients 2, 5 and more than 10 years after mastectomy. 81
Totale 9.987
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.654
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.654
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.570 0 0 0 0 0 297 356 197 276 185 219 40
2020/20211.233 128 61 119 30 168 45 86 165 67 103 54 207
2021/20221.942 3 157 15 79 406 312 23 79 124 37 52 655
2022/20232.324 323 178 132 220 295 372 18 188 424 9 140 25
2023/20242.001 351 251 253 114 273 346 23 52 39 21 36 242
2024/20251.350 31 237 44 352 331 355 0 0 0 0 0 0
Totale 17.431